中(zhong)證(zheng)網訊(記者 張玉潔(jie))長生(sheng)生(sheng)物(wu)(002680)7月(yue)24日晚間發布關于公(gong)(gong)司股票(piao)(piao)交(jiao)易實(shi)(shi)施(shi)其(qi)他風(feng)(feng)險(xian)警示暨子公(gong)(gong)司停(ting)產的公(gong)(gong)告。公(gong)(gong)司7月(yue)25日開(kai)(kai)市起停(ting)牌一(yi)天,7月(yue)26日開(kai)(kai)市起被實(shi)(shi)施(shi)其(qi)他風(feng)(feng)險(xian)警示,公(gong)(gong)司股票(piao)(piao)簡稱由“長生(sheng)生(sheng)物(wu)”變(bian)更(geng)為(wei)“ST 長生(sheng)”,公(gong)(gong)司股票(piao)(piao)交(jiao)易日漲跌(die)幅(fu)限(xian)制為(wei)5%。
實施其他風險警示
公(gong)告(gao)顯示,2018年(nian)7月(yue)15日(ri),國家藥(yao)(yao)品監(jian)督(du)管(guan)理(li)(li)局(ju)網站(zhan)披(pi)露了《關(guan)于長(chang)春(chun)長(chang)生生物科技有限責任(ren)公(gong)司違(wei)法違(wei)規生產凍干(gan)人(ren)用狂犬(quan)病疫苗的(de)通告(gao)》,2018年(nian)7月(yue)18日(ri),公(gong)司全資子公(gong)司長(chang)春(chun)長(chang)生收到《吉林省食品藥(yao)(yao)品監(jian)督(du)管(guan)理(li)(li)局(ju)行政(zheng)處罰決定書(shu)》。
近日(ri),吉林省(sheng)食品藥(yao)品監督管理局已(yi)收回長(chang)春長(chang)生狂犬(quan)(quan)病疫(yi)苗(miao)藥(yao)品GMP證(zheng)(zheng)書。目(mu)前(qian)長(chang)春長(chang)生停(ting)止(zhi)狂犬(quan)(quan)病疫(yi)苗(miao)生產(chan)及銷售。子(zi)公司所有產(chan)品已(yi)被(bei)暫(zan)停(ting)批簽發。目(mu)前(qian)除百白破聯合疫(yi)苗(miao)、凍干(gan)人用狂犬(quan)(quan)病疫(yi)苗(miao)產(chan)品被(bei)責(ze)令停(ting)產(chan)外,公司經(jing)研究決定(ding)對公司其他產(chan)品也采(cai)取全面(mian)自(zi)主(zhu)停(ting)產(chan),以上生產(chan)車間在停(ting)產(chan)期間自(zi)查自(zi)糾,進行全面(mian)、徹底(di)的整改。目(mu)前(qian)復產(chan)時間不確定(ding)。公司生產(chan)經(jing)營(ying)活動受到(dao)嚴重影(ying)響且預(yu)計在三個月內(nei)不能恢復正常,根據《深圳證(zheng)(zheng)券交易所股票上市規則》13.3.1 條規定(ding),公司股票自(zi)復牌之日(ri)起(qi)將實施其他風(feng)險警(jing)示。
2018年7月23日下(xia)午15時,長(chang)(chang)春市(shi)長(chang)(chang)春新區公(gong)(gong)安(an)分局依據吉(ji)林(lin)省(sheng)食品藥品監督管理(li)局《涉嫌犯罪(zui)(zui)案(an)(an)件移送(song)書(shu)》,對長(chang)(chang)春長(chang)(chang)生(sheng)生(sheng)產凍(dong)干人(ren)(ren)用狂犬病疫苗涉嫌違(wei)法犯罪(zui)(zui)案(an)(an)件立案(an)(an)調查,將主要涉案(an)(an)人(ren)(ren)員公(gong)(gong)司(si)董(dong)事(shi)長(chang)(chang)、3名(ming)公(gong)(gong)司(si)高管和(he)2名(ming)中層人(ren)(ren)員帶至公(gong)(gong)安(an)機關(guan)依法審查。公(gong)(gong)司(si)已(yi)經(jing)披(pi)露了《關(guan)于董(dong)事(shi)長(chang)(chang)及(ji)部分高管無法正(zheng)常履職的公(gong)(gong)告》。以上被(bei)公(gong)(gong)安(an)機關(guan)帶走的六(liu)人(ren)(ren)中有(you)兩名(ming)公(gong)(gong)司(si)董(dong)事(shi)。
嚴重影響下半年業績
長生(sheng)生(sheng)物(wu)表示,隨著狂犬疫苗事件的持續發(fa)酵,導致長春長生(sheng)其他產品生(sheng)產和銷售(shou)(shou)受到重(zhong)大影(ying)響,目(mu)(mu)前公(gong)司(si)所有產品批簽發(fa)暫停,公(gong)司(si)將組(zu)織自(zi)查(cha)隊伍進行自(zi)查(cha)自(zi)糾,進行全面、徹底的整改。目(mu)(mu)前復產時(shi)間尚不確(que)定(ding)。本次(ci)事件將會對公(gong)司(si)2018年下(xia)半(ban)年業績(ji)產生(sheng)重(zhong)大負面影(ying)響,同時(shi)由于本次(ci)違規事項,預計對未來公(gong)司(si)疫苗銷售(shou)(shou)將存在一定(ding)的阻礙,對未來經營業績(ji)也(ye)將產生(sheng)重(zhong)大影(ying)響,影(ying)響程度尚不確(que)定(ding)。
受疫苗事件影響,近日多家基(ji)金公司下調長(chang)生生物估值(zhi)。招商基(ji)金、博時基(ji)金和易方(fang)達調整后的(de)長(chang)生生物估值(zhi)價格為7.71元/股。
長生(sheng)(sheng)生(sheng)(sheng)物(wu)大股(gu)(gu)東、董監高(gao)被實(shi)施(shi)限售也影(ying)(ying)響(xiang)到其股(gu)(gu)權質押機構興業證(zheng)(zheng)券(quan)的(de)表現。興業證(zheng)(zheng)券(quan)今日發布(bu)公告稱,虞臣潘(pan)、張洺豪分別質押長生(sheng)(sheng)生(sheng)(sheng)物(wu)0.11億股(gu)(gu)和(he)1.67億股(gu)(gu),待購回金額6.75億元; 鑒于長生(sheng)(sheng)生(sheng)(sheng)物(wu)已被國(guo)家藥(yao)監局、證(zheng)(zheng)監會立(li)案調查,深交(jiao)所(suo)對(dui)長生(sheng)(sheng)生(sheng)(sheng)物(wu)大股(gu)(gu)東、董監高(gao)所(suo)持股(gu)(gu)份(fen)實(shi)施(shi)限售,公司將實(shi)時跟蹤事態發展,及時評(ping)估(gu)對(dui)公司經(jing)營狀況的(de)影(ying)(ying)響(xiang)并作出應(ying)對(dui)。
此前(qian),長(chang)(chang)生生物(wu)公告稱,公司(si)控股(gu)股(gu)東張(zhang)洺(ming)豪將其(qi)持(chi)有的7336.24萬股(gu)股(gu)份進行(xing)補充質押,質權人(ren)為(wei)興業證券。公開(kai)資料(liao)顯示,張(zhang)洺(ming)豪是長(chang)(chang)生生物(wu)實控人(ren)高(gao)俊(jun)(jun)芳之(zhi)子(zi),與高(gao)俊(jun)(jun)芳、張(zhang)友奎(高(gao)俊(jun)(jun)芳丈夫)為(wei)公司(si)一致行(xing)動人(ren),截至(zhi)公告披露(lu)日,三人(ren)合計持(chi)有公司(si)近3.57億(yi)股(gu),占公司(si)股(gu)本的36.66%。其(qi)中,張(zhang)洺(ming)豪持(chi)有長(chang)(chang)生生物(wu)約1.74億(yi)股(gu)股(gu)份,累計質押近1.67億(yi)股(gu),占公司(si)股(gu)本比17.14%,占其(qi)持(chi)股(gu)比例(li)為(wei)95.86%。
中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)(wang)聲(sheng)(sheng)明:凡本(ben)(ben)網(wang)(wang)(wang)(wang)注明“來源(yuan)(yuan):中(zhong)(zhong)(zhong)國(guo)證(zheng)(zheng)券(quan)(quan)(quan)報·中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)(wang)”的(de)所有作品(pin)(pin),版權均屬于中(zhong)(zhong)(zhong)國(guo)證(zheng)(zheng)券(quan)(quan)(quan)報、中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)(wang)。中(zhong)(zhong)(zhong)國(guo)證(zheng)(zheng)券(quan)(quan)(quan)報·中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)(wang)與作品(pin)(pin)作者聯合聲(sheng)(sheng)明,任(ren)何組織未經中(zhong)(zhong)(zhong)國(guo)證(zheng)(zheng)券(quan)(quan)(quan)報、中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)(wang)以及作者書面授(shou)權不(bu)得轉載、摘編或利用其(qi)它(ta)方式(shi)使用上(shang)述(shu)作品(pin)(pin)。凡本(ben)(ben)網(wang)(wang)(wang)(wang)注明來源(yuan)(yuan)非中(zhong)(zhong)(zhong)國(guo)證(zheng)(zheng)券(quan)(quan)(quan)報·中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)(wang)的(de)作品(pin)(pin),均轉載自其(qi)它(ta)媒體(ti),轉載目(mu)的(de)在于更好服務讀者、傳(chuan)遞信息之需(xu),并不(bu)代表本(ben)(ben)網(wang)(wang)(wang)(wang)贊同其(qi)觀點(dian),本(ben)(ben)網(wang)(wang)(wang)(wang)亦不(bu)對其(qi)真(zhen)實性負(fu)責,持異(yi)議者應與原出處單位主張權利。
特別鏈接:政府部門交易機構證券期貨四所兩司新聞發布平臺友情鏈接版權聲明
關于報社關于本站廣告發布免責條款
中國證券報社版權所有,未經書面授權不得復制或建立鏡像 經營許可證編號:京B2-20180749 京公網安備0-1
Copyright 2001-2018 China Securities Journal. All Rights Reserved
中(zhong)國證券報社版(ban)權所(suo)有,未經書面授權不得(de)復制或建(jian)立鏡像
經(jing)營許可(ke)證編號:京(jing)B2-20180749 京(jing)公網安備0-1
Copyright 2001-2018 China Securities Journal. All Rights Reserved